Gabriel J. Robbie

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

Gabriel J. Robbie, Ryan Criste, William F. Dall’Acqua et al. · Antimicrobial Agents and Chemotherapy · 2013 · 353 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Akshay S. Desai, David J. Webb, Jörg Täubel et al. · New England Journal of Medicine · 2023 · 261 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +14

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Mark D. Rothmann, Jogarao Gobburu, Gabriel J. Robbie et al. · PubMed · 2002 · 240 citations

Medicine, Oncology, Pharmacology +14

Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Michelle Petri, Daniel J. Wallace, Alberto Spindler et al. · Arthritis & Rheumatism · 2013 · 240 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

D. J. Wallace, M. Pétri, Kyriakos A. Kirou et al. · Annals of the Rheumatic Diseases · 2011 · 228 citations

Pharmacy, Immunology, Pharmacology +17